David. you, Thank
from We we one excited earlier in in advancing call, fourth Therapeutics. and of very Dr. design Chamberlain, he's about the excellent progress and Mark hired our As launch I pediatric halfway both made current and to that and trial on the This initial during second this year. getting this expect of safety incumbent LP-XXX which is early we clinical mentioned we're at ongoing trial Starlight CNS the is type efficacy of adult the enrolled. adult on areas half signal during the over quarter, is cancers, the Phase and our trial, point, in
We clinical will share the of this coming more on trial in the progress weeks.
yet should was on focus look that exhibited in preclinical born cancers of naturally in data initial LP-XXX, and cancers Starlight's of had vitro it silico-based at sensitivity Now in billions it evidence damage and in the We exquisite points as and came brain of from observations. profile, data given actually essentially cancers we the levels PTGRX to given we to in from CNS not gone very repair the And screens vivo quickly and moved be was to and the GBM brain observations other clear that several vivo given suggesting design. DNA genomic or interactome those saw was cancers. vitro to that sensitive
advances we the are both low therapies. insights. We can pediatric, XXX,XXX patients in investors rate and, me as fiber think about of our target. the course, this super which impact we of on to many we'll very globally, several the potential cancers of And there targeted positive Let XXX% be Lantern, is on unique in background share is owned the some we asset, over that Starlite have survival these Starlight, cancer our shareholders. cancers, another putting, believe and by monetize the adult patents is Therapeutics course, despite
GBM We designation have and for ATRT. an orphan already
disease We have designation. a also rare pediatric
one We have collaborators. and Hopkins, children's world-class the our collaborators San brain with UT is tumor Antonio Health which newer network, of
Additionally, there central system types nervous in of are cancer. over XXX brain
a area. it's So wide open
will high-grid maximum of Ia them and study gliomas, to other tolerated early are and be XX% of we GBM some Although the those Phase enrolling patients There of many dose. And brain tend has be to think therapies. in future be primary after. determine secondary drug other startup the a pivotal both XXX cancer this of and option we brain an in Starlight going that cancers, can do
Now about little are trials talk planned STAR let's a bit for that XXX. the
LP-XXX jointly will Phase done to in sponsored Ib/II the the be mentioned, is obtained data excess for our through, I safety owned Lantern. Starlight and in the CNS for this by other As will to the total globally being both dosage and about Lantern Phase tumors range wholly I be by used brings I be billion future trial, which $X about solid in a in $XX halfway subsidiary, and indications The billion, markets advance think $XX trial market to Phase and indications, now The billion. Therapeutics. in we to plus of are the of
So be spent understanding we therapies. particularly patient with while molecule, this and you developing excited drug can we're most triggers sensitive the other it'll where of of its understanding response, profile, indications understanding combining see why the also then molecular about around a lot time unique patents this
this the is let to the the once well I I molecules receive into of alone Phase X So characterized most data. getting Phase now we prior
go excited very Starlight we'll trial. into Therapeutics. I have year And the and that more this combination trials and this on have are CNS importantly, about allow Phase we'll data data into molecule, us We with to
this to Germany. our of working was to 'XX part cryptophysin announced Magic Bellefield the antibody we the on in not area, accomplished later It's the program late is advancements our perhaps crush Much with Bullet area at Seawell's Dr. early-stage in lab as working going a team We area able our University we're in combination Consortium. high-growth in go also another work which believe take of were year, been advance of of worked on that proven development. this is stage oncology. moderate develop a preclinical well expensive drug that the in area and only in not need, ADC Earlier we're of very Let's concept HERX but cost promising proof for unmet development, of of bioconjugation an a antibody is in it conjugates. conjugate, highly this only This and it really after has but expression. that area the we drug synthesis, which and high
very number And some drug than MMAE. the potent Our very, lines. activity, of kill actually we're a or was ADCs cancer cell it the efficient importantly, rates that with a across of XXx in single-digit XX% importantly, about XX% was that antitumor values we very picomolar ] more it payload payload the more about cells used interest are challenging cancer us cryptophycin to that cells even the range averaged existing of and of gave the more common cancers. [ saw in the a This nanomolar killed ECXX more is means
payload is think things an we lot it, that asset us even We're to to believe of a out is findings. do data the Starlight. is to now of biomarker develop very understanding doing It to licensable, we can how we taking pinpoint as after understand repeat and we one obtain first of it? need a importantly, other be additional we to And studies most correlates can important going do energy go do after and aware what and partnerable response. a validate these money. driving genomic time deeper again, this or be most we be efficacy. really these kind We of in we're So spin save cancers? can And most we approach. what studies of critical things and This is of these what further that think How the really can is
up great and II a I. So that lot that to now following our in are assets existing again, we've assets got are clinical trial of Phase Phase
with want want update and to business educate also share critical area and to A of is you programs launched I take an inform, to an with we're details this to It's major focus the informational and that on. we Wednesday. an webinar some some stakeholders, our we to be about efforts. better want time at. call general that area on And effort we oncology with updates. part the public community our calling our and It's on
CNS in be a leading first by our be another be on Fox that rolled Treat and webinar Dr. effort, on the brain will in very about our and a is history and enrolled, cancers. heavily about store drugs going We're him seem of be Mark failed of hosting a tremendous clinical Center. of malignancies, will will be Dr. expert he'll out. adult focused first be which This very on regimens, fortunate candidate. resource and CNS from and across and brain history drug humanoid Dr. trials, have webinar of series that and will tumors own knowledge our be coming to hosting cancers, webinar followed LP-XXX. So as successful cancers, pediatric Chase webinar this and other CNS to Chamberlain. a be challenging Cancer series cancers, is virtually he to He's focus of followed will will CNS pancreatic our our We're that Fox to Starlight, about responsive LP-XXX webinar webinar Chase by and Starlight Joseph halfway in in This will with with second lung again both of drug on part have trial, month. very Treat their and the and
aggressive drives that that recurrent, more higher same the molecule. the PTGRX. cancers seems the And these activity In of it levels have are they actually of fact, markers
the trials from silico work. So better and the using seems have we're obviously design our and have we recurrent, worked from our inversely, now And to and Phase to I try the the aggressive drug data data going future so to preclinical far. the more in
LP focuses for X, earlier mentioned a ] relapsed it was past very which selected. will will on or quarter, TPXX agent XXX, mutation-agnostic clinical DNA in call, and XXX, in presented Phase a by this trial poster own refractory April potent XXXX of It solid LP be I agnostic and lymphomas As our on highly other [ is our damaging AACR on and John Ia/Ib Chao Lee focus that LP in advance you more in capabilities many that the quarter. recently we know, and later-stage patients, Radar to believe, development also initial and size, tumors. coming becoming XXX, sites as is drug progressing, standard more early-stage and expect scope dosed bring to we to on a identification. oncology we we've for biomarker announced development continues therapy patient AI-driven and and and in for both patients combination
RADR has classes now The inhibitors points is by on surpassed additional to antibodies, of $XXX has DNA believe we strategic damaging of end over checkpoint this with data RADR XX billion compounds, projected billion, agents. the and including the oncology-focused of over scope focus well and reach year. broadened data
comprise algorithms improve we all will development with clinical of data the and co-piloting RADR's and from module us RADR. obtained in we'll combination to data of over and believe have data and the data and optimal advance and the sets such points that biopsy as dosage the a efficiency aim advancements liquid modules kind These to preclinical being define Additionally, along speed, and the Power from drug being these those functional interaction automation help in X the the points, from data precision of And drug code incorporated that studies studies, capabilities. into associated are platform. our
the focused and quarter, most AI the again, and the for is which oncology believe, road discussing will platform second near-term use we for webinar largest the host cases During drug we a RADR, development. map Wednesday, the
year for So us. XXXX was a pivotal
meaningful Our started clinical cancer. They are therapies into now becoming entering insights trials. in to their journey patient
for lives with Our effective By future, towards setting patients trajectory on collective us and exciting exciting we're and of efforts company, improving a cancer where lot the options. more treatment objectives. and generated have dedication an a the other we shift our fostered economically of transformational XXXX,
a year our expect We Lantern programs. breakthrough for and be to XXXX
we -- top expand of advance XX like We Specifically, for LP-XXX. Phase to our I milestones. clinical we'd have our and kind want trial to share
non-Hodgkin's some LP lymphomas and in accelerate expect other in enrollment cancers. to We responsive XXX
enrollment expand lung never where in about of and is trial Xx will into targeted We of harmonic sites the cell Asia, higher. non-small incidence cancer smoker
opportunities billion be to small, companies, that RADAR's develop companies, biopharma with data XXX points explore with announcing. and expand going We're and both and to biopharma licensing over partnership we'll additional platform large collaborations
to by trial Therapeutics of expect and towards Phase adult also early Starlight year. perhaps a end I the trial next this a Phase year progress We Ib/II clinical pediatric or
into We I will IND with to all existing for launch. support our develop Phase future of partnering further a ADC going drugs. our also development drugs preclinical We're X programs or approved to combination
a planning fact, of couple In growing our management. continue maturing is trials our this additional years. and of focus disciplined over for and next platform the area for importantly, then clinical on We're and big capabilities most and fiscal our financial operations
And toward closing, really keep partners solving oncology on problems my believe our with And be stakeholders webinars, in wanted are a Together, real-world year we better and solutions enable this places in AI and alter cost support. that we'll place way express great high-value we time targeted communications rapid lighting same our this line think providing we the both their in and We to So for our future proprietary gratitude And at want of development with that, updates at a meetings and like of unwavering very of brighter a to to medicine discovery. now new putting genomically drug for the I With emergence of AI. in in age call the any era open I'd golden in therapies. medicine questions time, to to of all share to to routinely, those also releases. and our to path high. through forefront I team, interested roadshows, the investor the and parties -- due a is press call like or a in the what development us clarifications.
